Loading news...
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L purchased 50,000 shares of Benitec Biopharma stock in a transaction that occurred on Tuesday, December 23rd. The shares were purchased at an average cost of $12.85 per share, with a total value of $642,500.00. Following the transaction, the director directly owned 9,620,075
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L bought 16,836 shares of the firm's stock in a transaction that occurred on Friday, December 26th. The stock was purchased at an average cost of $13.10 per share, with a total value of $220,551.60. Following the completion of the purchase, the director
The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L bought 10,215 shares of the business's stock in a transaction on Thursday, December 18th. The stock was purchased at an average price of $11.24 per share, with a total value of $114,816.60. Following the completion of the transaction, the director directly owned
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Benitec Biopharma (BNTC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
– Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301–
In the past week or so, beneficial owners Carl Icahn and Mario Gabelli made some big bets in Monro Inc.
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten public offering of 5,930,000 shares of its common stock and a concurrent registered direct offering of 1,481,481 shares of its common stock with long-term investor Suvretta Capital.
HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and intends to conduct a concurrent registered direct offering of its common stock with long-term investor Suvretta Capital. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to a number of additional shares of its common stock equal to 15% of the total number of shares of common stock (and pre-funded warrants to purchase common stock in lieu thereof) sold in the underwritten offering, on the same terms and conditions. The offerings are expected to close on November 7, 2025, subject to customary closing conditions. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today provides positive interim clinical results for the BB-301 Phase 1b/2a Clinical Trial. Following administration of BB-301, Cohort 1 patients demonstrated significant and sustained improvements across multiple clinical measures including dysphagic symptom burden, post-swallow residue accumulation, time required to consume fixed volumes of liquid, as well as improved pharyngeal closure during swallowing. All six patients enrolled into Cohort 1 met the formal statistical criteria for response to BB-301, representing a 100% response rate. Following review of these encouraging interim data, the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BB-301 for the treatment of OPMD with dysphagia. BB-301 was also previously granted Orphan Drug Designation from both the FDA and European Medical Association (EMA).
Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine analysts that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to
Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 HAYWARD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its full year ended June 30, 2025.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Benitec Biopharma (BNTC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
The average of price targets set by Wall Street analysts indicates a potential upside of 66% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here is how Benitec Biopharma Limited (BNTC) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.